Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

兴奋剂 胰高血糖素样肽1受体 肥胖 受体 医学 内分泌学 减肥 药理学 内科学 体重 糖尿病 脂肪组织 临床试验
作者
Sean Wharton,Louis J. Aronne,Adam Stefański,Nasreen Alfaris,Andreea Ciudin,Koutaro Yokote,Bruno Halpern,Alpana P. Shukla,Chunmei Zhou,Lisa Farmer Macpherson,Sheryl Elaine Allen,Nadia N. Ahmad,Suzanne R. Klise
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:393 (18): 1796-1806 被引量:230
标识
DOI:10.1056/nejmoa2511774
摘要

BACKGROUND: Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. METHODS: In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity without diabetes mellitus. The primary end point was the percent change in body weight from baseline to week 72, as assessed according to the treatment-regimen estimand in the intention-to-treat population. RESULTS: A total of 3127 patients underwent randomization. The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo). Among the patients in the orforglipron 36-mg group, 54.6% had a reduction of 10% or more, 36.0% had a reduction of 15% or more, and 18.4% had a reduction of 20% or more, as compared with 12.9%, 5.9%, and 2.8% of the patients, respectively, in the placebo group. Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo. Adverse events resulted in treatment discontinuation in 5.3 to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group. The most common adverse events with orforglipron were gastrointestinal effects, which were mostly mild to moderate. CONCLUSIONS: In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. (Funded by Eli Lilly; ATTAIN-1 ClinicalTrials.gov number, NCT05869903.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Ceylon发布了新的文献求助10
刚刚
Echen发布了新的文献求助10
1秒前
PatrickL完成签到,获得积分10
1秒前
科研通AI6.3的应助被单虽然采纳,获得10
1秒前
1秒前
2秒前
超级涵山发布了新的文献求助10
2秒前
古芍昂发布了新的文献求助10
2秒前
可爱的函函的应助被小小迷糊采纳,获得10
3秒前
科研大印完成签到,获得积分10
4秒前
脏脏包发布了新的文献求助10
4秒前
5秒前
5秒前
调皮元珊发布了新的文献求助10
5秒前
李爱国的应助被尊敬的雨竹采纳,获得10
6秒前
和谐的雪瑶完成签到,获得积分20
6秒前
念兹在兹完成签到,获得积分10
6秒前
CarryLJR的应助被NiMing采纳,获得10
7秒前
chen发布了新的文献求助10
7秒前
7秒前
cv发布了新的文献求助10
8秒前
星期日发布了新的文献求助10
8秒前
Echen完成签到,获得积分10
8秒前
9秒前
共享精神的应助被小粒橙采纳,获得10
10秒前
大个的应助被PhD采纳,获得10
11秒前
junge发布了新的文献求助10
11秒前
彭于晏的应助被zzyh采纳,获得10
11秒前
淡定完成签到,获得积分10
12秒前
Adax发布了新的文献求助10
12秒前
生动的芝麻完成签到,获得积分10
12秒前
12秒前
13秒前
科研通AI2S的应助被糊涂的电话采纳,获得10
14秒前
14秒前
淡定发布了新的文献求助30
14秒前
搜集达人的应助被自然的含蕾采纳,获得10
15秒前
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178695
求助须知:如何正确求助?哪些是违规求助? 9569449
关于积分的说明 21804643
捐赠科研通 7773744
什么是DOI,文献DOI怎么找? 3432903
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478500